



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

2 April 2020 (#18)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notice

Updates on NIAID Funding for SARS-CoV-2 and COVID-2019 Research: By issuing the new **NIAID Emergency NOSI**, NIAID can further reduce the time to award for meritorious applications.

- **NOT-AI-20-034:** Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. NIAID is therefore offering Competitive Revisions to active NIAID grants addressing research objectives described in this notice.

NOT-TR-20-012 Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19). National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice:

Codes	FOA Title	Applicable Dates
UG3/UH3	PAR-17-465 : Bench Testing Therapeutic/Indication Paring Strategies	Jun 26, 2020
U34	PA-18-462 :Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)	Jun 16, 2020 Oct 16, 2020
U01	PAR-18-332 : Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)	Jun 05, 2020 Oct 05, 2020

FDA Coronavirus Treatment Acceleration Program (CTAP): FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness. Given the urgent nature of the pandemic and the number of companies and researchers developing COVID-19 related therapies, the following numbers may change frequently. Our current snapshot is:

- 10 therapeutic agents in active trials
- Another 15 therapeutic agents in planning stages

Please send requests for product development for proposed COVID-19 uses and drug development to: COVID19-productdevelopment@fda.hhs.gov.

[Bill & Melinda Gates Foundation, Wellcome, and Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19](#) The Bill & Melinda Gates Foundation, Wellcome, and [Mastercard](#)

today committed up to \$125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The partners are committed to equitable access, including making products available and affordable in low-resource settings. The Gates Foundation and Wellcome are each contributing up to \$50 million, and the Mastercard Impact Fund has committed up to \$25 million to catalyze the initial work of the accelerator. [MBGF Announcing the COVID-19 Therapeutics Accelerator](#). [The benefits of hydroxychloroquine being investigated in multi-site clinical trial launching in April](#) To learn more about the COVID-19 PEP Study, including how to join the study, visit www.covid19pepstudy.org.

- **Contact:** Bill & Melinda Gates Foundation media@gatesfoundation.org
- **Wellcome:** Maggie Stratton +44(0)20 7611 8609 m.stratton@wellcome.ac.uk
- **Mastercard:** Toju Egbebi toju.egbebi@Mastercard.com

[Research to support COVID-19 response in humanitarian settings from Elrha](#). Elrha is launching an urgent funding call for research proposals to support the COVID-19 response in humanitarian settings in low and middle-income countries (LMICs). The call aims to fund public health research that will produce robust findings that will contribute to the effectiveness of the current humanitarian response and increase the evidence base for future responses to similar infectious disease outbreaks. **Deadline:** Round 1: 18.00 (GMT+1) on 13 April 2020

1. Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-ES-19-011](#)

Type: R21

Application Due Date: May 1, 2020; June 1, 2020; July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) is intended to support *novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data*. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.

Budget: NIEHS intends to commit \$800,000 per year for fiscal years 2020, 2021, 2022, 2023 to fund 4-5 awards each year. Future year amounts will depend on annual appropriations. The combined budget for direct costs for the 2-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizel*
e: lizelk@sun.ac.za | t: +27 21 808 2105